- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2015
- Public Summary Document (PSD) November 2015 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2015 PBAC Meeting - Word
Omalizumab – November 2015
Omalizumab: 75 mg/0.5 mL injection, 1 x 0.5 mL syringe; 150 mg/mL injection, 1 pack, Xolair®
Last updated
18 April 2016